Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 31, 23, 3, 53 and 18 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

89bio Inc
ABIONYX Pharma SA
Afimmune Biopharma Ltd
Agentix Corp
Albireo Pharma Inc
Alfasigma SpA
Altimmune Inc
Amgen Inc
Amicogen Inc
AptamiR Therapeutics Inc
Ascletis Pharma Inc
Asdera LLC
AstraZeneca Plc
AtoGen Co Ltd
BAR Pharmaceuticals Srl
Bast Biotechnology LLC
Bausch Health Companies Inc
Beijing FuKangren Bio-pharm Tech Co Ltd
Betagenon AB
Bird Rock Bio Inc
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
Chemomab Therapeutics Ltd
China NT Pharma Group Co Ltd
CohBar Inc
Corcept Therapeutics Inc
Corvidane
CVI Pharmaceuticals US Inc
Dr. Falk Pharma GmbH
DURECT Corp
Eli Lilly and Co
Enspire Bio Inc
Esperion Therapeutics Inc
Eternygen GmbH
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Fujian Cosunter Pharmaceutical Co Ltd
Future Medicine Co Ltd
Galmed Pharmaceuticals Ltd
GemVax & KAEL Co Ltd
GeneScience Pharmaceuticals Co Ltd
Gila Therapeutics Inc
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
HCW Biologics Inc
Hepion Pharmaceuticals Inc
HK inno.N Corp
HysensBio Corp
Immuron Ltd
Inmune Bio Inc
Inorbit Therapeutics AB
Inventiva SA
Ionis Pharmaceuticals Inc
J2H Biotech
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Kaleido Biosciences Inc
Kinomedica Pty Ltd
KoBioLabs Inc
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
Liminal BioSciences Inc
Lipidio Pharmaceuticals Inc
Macrophage Pharma Ltd
Macrophage Therapeutics Inc
Madrigal Pharmaceuticals Inc
Metacrine Inc
Micelle BioPharma Inc
Mina Therapeutics Ltd
Nano Intelligent Biomedical Engineering Corp
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
Nivarta Inc
Novartis AG
NovMetaPharma Co Ltd
NovoBiome SAS
NuSirt Biopharma Inc
Oncocross Co Ltd
PegBio Co Ltd
Petri Bio LLC
Pfizer Inc
PharmaKing Co Ltd
Phenex Pharmaceuticals AG
Poxel SA
PTC Therapeutics Inc
Renova Therapeutics Inc
Sagimet Biosciences Inc
Salix Pharmaceuticals Ltd
Scohia Pharma Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
SparkBioPharma Inc
Sveikatal Inc
Synthetic Biologics Inc
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
TES Pharma SRL
Theratechnologies Inc
Uni-Bio Science Group Ltd
Verseon Corp
VGI Health Technology Ltd
Vidasym Inc
Viking Therapeutics Inc
Zedira GmbH
Zydus Lifesciences Ltd